Navigation Links
ALSIUS CORPORATION PREPARED TO INVALIDATE ZOLL TEMPERATURE MANAGEMENT PATENTS
Date:2/3/2009

IRVINE, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Alsius Corporation (Nasdaq: ALUS), the worldwide leader in intravascular temperature management (IVTM(TM)) therapies for critically ill patients, today announced that it is prepared to respond aggressively to the patent lawsuit brought against it by ZOLL Circulation, Inc., a subsidiary of ZOLL Medical Corporation (Nasdaq: ZOLL). Alsius was sued by ZOLL based on two temperature management patents ZOLL purchased from a defunct competitor of Alsius'. Alsius believes that its patents do not infringe on the ZOLL patents, and that ZOLL's core temperature management patents are invalid. Alsius believes that it retains a dominant patent position in intravascular cooling that, among other things, precludes any competitor from marketing an intravascular cooling catheter for therapeutic hypothermia in patients who have had cardiac arrest or heart attack. ZOLL has not yet sold temperature management products based on ZOLL's patents.

About Alsius Corporation

Alsius, the worldwide leader in intravascular temperature management, develops, manufactures and sells proprietary products to precisely control patient temperature in hospital critical care settings. Controlling body temperature, through cooling and warming, is becoming the standard of care for patients in select critical conditions and those undergoing a variety of surgical procedures. Alsius markets a comprehensive suite of catheter-based intravascular temperature management products that address the largely unmet clinical need for effective, accurate, easy-to-use and cost-effective control of body temperature in critical care patients. For more information, visit www.alsius.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, with respect to Alsius' future financial or business performance. These statements are not guarantees of future performance and involve risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including the risks described from time to time in Alsius' filings with the Securities and Exchange Commission. These risks include, but are not limited to, the fact that Alsius must raise additional funds before the end of the second quarter of 2009 to continue its operations and finance the litigation described herein, uncertainty in the market for sales of medical equipment, and uncertainty in any complex litigation such as the litigation between Alsius and ZOLL described herein. Alsius undertakes no duty to update any forward-looking statements made herein, except as required by law.


'/>"/>
SOURCE Alsius Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Alsius Corporation Pre-Announces Record Fourth Quarter and Full Year 2008 Revenue
2. Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress
3. Alsius Corporation to Host Third Quarter 2008 Financial Results Conference Call on November 6
4. Alsius Corporation Awarded Three-Year Agreement With Premier, Inc.
5. Alsius Corporation Awarded Three-Year Agreement with HealthTrust Purchasing Group
6. Alsius Corporation Awarded Three-Year Agreement With MedAssets Supply Chain Systems
7. Alsius Corporation Receives Regulatory Approval in China and Mexico
8. Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results
9. Alsius Corporation Announces Program for Early Exercise of Warrants
10. Alsius Corporation to Host Third Quarter 2007 Financial Results Conference Call/Webcast on November 13, 2007
11. Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
(Date:6/24/2016)... ... 24, 2016 , ... National recruitment firm Slone Partners is pleased ... and genomics experience, as Vice President of North American Capital Sales at HTG ... leading the sales team in the commercialization of the HTG EdgeSeq system and associated ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas ... Brasil as the company,s second affiliate in Latin America . ... ... of Astellas Farma Colombia ... ...
(Date:6/23/2016)... , June 23, 2016  Experian ... integrating and transforming the patient payment and ... several innovative new products and services that ... its revenue cycle offerings. These award-winning solutions ... efficient workflows, remain compliant in an ever-changing ...
Breaking Medicine Technology: